Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Research & Development (2016 - 2025)

Rocket Pharmaceuticals' Research & Development history spans 10 years, with the latest figure at $29.3 million for Q4 2025.

  • For Q4 2025, Research & Development fell 21.44% year-over-year to $29.3 million; the TTM value through Dec 2025 reached $142.0 million, down 17.07%, while the annual FY2025 figure was $142.0 million, 17.07% down from the prior year.
  • Research & Development for Q4 2025 was $29.3 million at Rocket Pharmaceuticals, down from $34.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $51.4 million in Q2 2023 and bottomed at $24.5 million in Q2 2021.
  • The 5-year median for Research & Development is $41.6 million (2022), against an average of $39.5 million.
  • The largest YoY upside for Research & Development was 82.93% in 2021 against a maximum downside of 34.09% in 2021.
  • A 5-year view of Research & Development shows it stood at $33.0 million in 2021, then skyrocketed by 51.55% to $50.0 million in 2022, then decreased by 16.57% to $41.7 million in 2023, then fell by 10.51% to $37.4 million in 2024, then fell by 21.44% to $29.3 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Research & Development are $29.3 million (Q4 2025), $34.1 million (Q3 2025), and $42.7 million (Q2 2025).